Chengdu-based Beyang Therapeutics closed an oversubscribed Series A of nearly $30 million, co-led by Legend Capital and Shanghai Healthcare Capital. Proceeds will support the ExCEED AI/molecular-design platform, clinical and preclinical programs and international development….
Boulevard Bio emerged from stealth with approximately $65 million in aggregate equity and convertible-note financing from Deerfield and affiliates. Its precision-immunology pipeline includes BLVD101, a dual BAFF/APRIL antibody with interim single-dose healthy-volunteer pharmacology supporting…
Bridge to Life completed $110 million of Series C equity and debt financing to expand the U.S. launch of its VitaSmart hypothermic oxygenated perfusion system, advance an organ-viability assessment tool, scale global operations and…
A peer-reviewed Nature Biotechnology study combines large-scale experimental mapping with deep learning to predict and design cell-surface-display elements for mRNA-encoded antigens. The researchers quantified more than 570 chimeric antigens, assigned translocation-strength labels to approximately…
Integrated DNA Technologies and University of California, San Francisco researchers reported UNCOVERseq, an in-cellulo workflow for nominating low-frequency CRISPR off-target sites across nucleases, high-fidelity Cas9 variants and base editors. In a benchmark set, the…
K2 Therapeutics appointed Ying Huang, Ph.D., as chief executive officer. Huang previously served as chief executive officer and a director of Legend Biotech, where he led the company during commercialization of CARVYKTI with Johnson…
Sentynl Therapeutics and Mereo BioPharma entered an option and license agreement for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease. Sentynl receives an option for U.S. commercialization and global manufacturing rights; Mereo retains rest-of-world commercial…
Shattuck Labs reported Phase 1 healthy-volunteer results for SL-325, a monoclonal antibody that blocks the TL1A receptor DR3. The company observed 3.7% anti-drug-antibody incidence and complete blockade of TL1A binding to DR3 for more…
Vaderis Therapeutics closed an oversubscribed $152 million Series B and announced initiation of the global Phase 3 HEROIC study of engasertib in moderate-to-severe hereditary hemorrhagic telangiectasia (HHT). The financing is expected to support planned…
Bicara Therapeutics announced a planned CEO succession and four additional senior-role changes around the pivotal development of ficerafusp alfa. President and COO Ryan Cohlhepp will become president and CEO on January 1, 2027; CEO…
